GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » Ending Cash Position

Hua Medicine (HKSE:02552) Ending Cash Position : HK$1,216.9 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Ending Cash Position?

Hua Medicine's Ending Cash Position for the quarter that ended in Dec. 2024 was HK$1,216.9 Mil.

Hua Medicine's quarterly Ending Cash Position declined from Dec. 2023 (HK$1,597.8 Mil) to Jun. 2024 (HK$1,441.3 Mil) and declined from Jun. 2024 (HK$1,441.3 Mil) to Dec. 2024 (HK$1,216.9 Mil).

Hua Medicine's annual Ending Cash Position increased from Dec. 2022 (HK$547.9 Mil) to Dec. 2023 (HK$1,597.8 Mil) but then declined from Dec. 2023 (HK$1,597.8 Mil) to Dec. 2024 (HK$1,216.9 Mil).


Hua Medicine Ending Cash Position Historical Data

The historical data trend for Hua Medicine's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine Ending Cash Position Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 1,223.47 826.81 547.90 1,597.82 1,216.88

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 547.90 963.94 1,597.82 1,441.29 1,216.88

Hua Medicine Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hua Medicine's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1559.681+-342.799
=1,216.9

Hua Medicine's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1429.409+-212.527
=1,216.9


Hua Medicine Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Hua Medicine's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Hua Medicine Business Description

Traded in Other Exchanges
N/A
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Executives
Hong Jane Xingfang 2202 Interest of your spouse
Chen Li 2101 Beneficial owner
Hlyy Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
Wuxi Pharmatech Investments (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd. 2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited 2201 Interest of corporation controlled by you
Nelsen Robert Taylor 2101 Beneficial owner
Venrock Management V, Llc 2102 Investment manager
Harvest Yuanxiang (cayman) Limited 2101 Beneficial owner
Arch Venture Fund Vii, L.p. 2101 Beneficial owner

Hua Medicine Headlines

No Headlines